English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214554
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Rationalizing antimicrobial therapy in the ICU: a narrative review

AuthorsTimsit, Jean-François; Bassetti, Matteo; Cremer, Olaf; Daikos, George; Waele, Jan de; Kallil, Andre; Kipnis, Eric; Kollef, Marin; Laupland, Kevin; Paiva, Jose‑Artur; Rodríguez-Baño, Jesús; Ruppé, Étienne; Salluh, Jorge; Taccone, Fabio Silvio; Weiss, Emmanuel; Barbier, François
KeywordsAntibiotic stewardship
Antimicrobial resistance
Empirical therapy
Critical illness
Carbapenem
Outcome
Sepsis
Issue Date2019
PublisherSpringer Nature
CitationIntensive Care Medicine 45: 172-189 (2019)
AbstractThe massive consumption of antibiotics in the ICU is responsible for substantial ecological side effects that promote the dissemination of multidrug-resistant bacteria (MDRB) in this environment. Strikingly, up to half of ICU patients receiving empirical antibiotic therapy have no definitively confirmed infection, while de-escalation and shortened treatment duration are insufficiently considered in those with documented sepsis, highlighting the potential benefit of implementing antibiotic stewardship programs (ASP) and other quality improvement initiatives. The objective of this narrative review is to summarize the available evidence, emerging options, and unsolved controversies for the optimization of antibiotic therapy in the ICU. Published data notably support the need for better identification of patients at risk of MDRB infection, more accurate diagnostic tools enabling a rule-in/rule-out approach for bacterial sepsis, an individualized reasoning for the selection of single-drug or combination empirical regimen, the use of adequate dosing and administration schemes to ensure the attainment of pharmacokinetics/pharmacodynamics targets, concomitant source control when appropriate, and a systematic reappraisal of initial therapy in an attempt to minimize collateral damage on commensal ecosystems through de-escalation and treatment-shortening whenever conceivable. This narrative review also aims at compiling arguments for the elaboration of actionable ASP in the ICU, including improved patient outcomes and a reduction in antibiotic-related selection pressure that may help to control the dissemination of MDRB in this healthcare setting.
Publisher version (URL)https://doi.org/10.1007/s00134-019-05520-5
URIhttp://hdl.handle.net/10261/214554
DOIhttp://dx.doi.org/10.1007/s00134-019-05520-5
ISSN0342-4642
E-ISSN1432-1238
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.